Sanofi-Aventis Drops Genasense After Genta Declines To Modify Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Genta says it was approached by Aventis “on several occasions” after a negative Oncologic Drugs Advisory Committee review in May about modifying the financial terms of the oblimersen collaboration, “but we declined to make those accommodations.”